TY - JOUR
T1 - Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
AU - Iwasaka, Sho
AU - Shono, Yuji
AU - Tokuda, Kentaro
AU - Nakashima, Kosuke
AU - Yamamoto, Yuzo
AU - Maki, Jun
AU - Nagasaki, Yoji
AU - Shimono, Nobuyuki
AU - Akahoshi, Tomohiko
AU - Taguchi, Tomoaki
N1 - Publisher Copyright:
© 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2020/12
Y1 - 2020/12
N2 - The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.
AB - The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85090312122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090312122&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2020.08.001
DO - 10.1016/j.jiac.2020.08.001
M3 - Article
C2 - 32893123
AN - SCOPUS:85090312122
SN - 1341-321X
VL - 26
SP - 1319
EP - 1323
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 12
ER -
